{"ticker": {"uuid": "c48faa0d-14c6-4d7d-a651-61f0c40adc1a", "symbol": "VISTN", "name": "Vistin Pharma ASA", "exchange": "OSL", "country": "NO", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Vistin Pharma ASA (OB: VISTN) Stock Ex-Dividend Deadline Approaches as Income Investors Weigh Payout Sustainability", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNallfWXNoQ2plazZsdTVGVGVVQjR1eVlCbEM5M2xZT2F5bml0VzQxR2p6cGp2TVBOMU9VN0ZMZDVObXhVNDNJOTZsakRGNHVTX3VnVDJrYUp4RVZHb0l1RHpWbTE4MXVtTExzUHhsc0lFVkFqVHpkRjJReEFsSEVLX3Zrbnl3cThmSzVsRDhJSUhrVU01OE1paVhvOFJZU1laLVRSQTRCU2tNalYzejI1NHhhMjA1Z01WYVlQSExPcnAzTmNBaGxLbzJ5Mmp4dEtFaG9HQkpCQ1hhRFR1dlBNSlhOSXIzOTNPZFVj?oc=5", "source_name": "foreignpolicyjournal.com", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistin Pharma ASA: First quarter 2025 financial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQTNXZ0k0ZlRBS1hHSjAwSElGVlFmUVJpRkFhTTJXbndScWFsejRmZ2dKUWxjY2ttTGk3bk1hQl82eDV5RmswUG9vMmlQeHZ5Z2ZHbTZDV1VWcEYyLW5XOVBWQVoyOWt3ZXVPcmc3V2FTWllDVjVGdTZwYUpfWGQ3dWxzTVRtcTl5aVlpN2hqeVVSMHE0czhKZjhCMVFnOVpJM0RvMXVjdC1FaTNiV3JFWHpJR0JvVUZXSlY5d29FMzkwV1hT?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-04-25T07:00:00+00:00", "published_display": "25 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VISTN Stock Price and Chart \u2014 OSL:VISTN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9EY3ZHOVpfRk1tUkFzeE5MWlN3LXpLOUtnTDNCZDl6alpJcGFaeldPUGk3UHZZd3ZOcVd5MFBYTWxRLWRuZm9LeUZ0M3BaYXM2eG8xMl8xZ2R2UQ?oc=5", "source_name": "TradingView", "published_at": "2022-03-10T08:00:00+00:00", "published_display": "10 Mar 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistin hands partner its opioid, CMO businesses", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1Ncmx1VE1KaVZTWXhuYzJDcVFsYUdKejBDSjg4ckpIRXFVaEs5UDJ6YWRNcWM2NWxMaEkzXzdIX0xDRXZvTmZrYmJjLUlnaHVPaXo2YlpvWThKMmJ2VW5FOEtfUTRmUElzX0hOSEdwS2EyUVYyUk5CQw?oc=5", "source_name": "BioPharma Dive", "published_at": "2017-07-13T07:00:00+00:00", "published_display": "13 Jul 2017 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Vistin Pharma ASA (OB: VISTN) Stock Ex-Dividend Deadline Approaches as Income Investors Weigh Payout Sustainability", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNallfWXNoQ2plazZsdTVGVGVVQjR1eVlCbEM5M2xZT2F5bml0VzQxR2p6cGp2TVBOMU9VN0ZMZDVObXhVNDNJOTZsakRGNHVTX3VnVDJrYUp4RVZHb0l1RHpWbTE4MXVtTExzUHhsc0lFVkFqVHpkRjJReEFsSEVLX3Zrbnl3cThmSzVsRDhJSUhrVU01OE1paVhvOFJZU1laLVRSQTRCU2tNalYzejI1NHhhMjA1Z01WYVlQSExPcnAzTmNBaGxLbzJ5Mmp4dEtFaG9HQkpCQ1hhRFR1dlBNSlhOSXIzOTNPZFVj?oc=5", "source_name": "foreignpolicyjournal.com", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistin Pharma ASA: First quarter 2025 financial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQTNXZ0k0ZlRBS1hHSjAwSElGVlFmUVJpRkFhTTJXbndScWFsejRmZ2dKUWxjY2ttTGk3bk1hQl82eDV5RmswUG9vMmlQeHZ5Z2ZHbTZDV1VWcEYyLW5XOVBWQVoyOWt3ZXVPcmc3V2FTWllDVjVGdTZwYUpfWGQ3dWxzTVRtcTl5aVlpN2hqeVVSMHE0czhKZjhCMVFnOVpJM0RvMXVjdC1FaTNiV3JFWHpJR0JvVUZXSlY5d29FMzkwV1hT?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-04-25T07:00:00+00:00", "published_display": "25 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VISTN Stock Price and Chart \u2014 OSL:VISTN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9EY3ZHOVpfRk1tUkFzeE5MWlN3LXpLOUtnTDNCZDl6alpJcGFaeldPUGk3UHZZd3ZOcVd5MFBYTWxRLWRuZm9LeUZ0M3BaYXM2eG8xMl8xZ2R2UQ?oc=5", "source_name": "TradingView", "published_at": "2022-03-10T08:00:00+00:00", "published_display": "10 Mar 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistin hands partner its opioid, CMO businesses", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE1Ncmx1VE1KaVZTWXhuYzJDcVFsYUdKejBDSjg4ckpIRXFVaEs5UDJ6YWRNcWM2NWxMaEkzXzdIX0xDRXZvTmZrYmJjLUlnaHVPaXo2YlpvWThKMmJ2VW5FOEtfUTRmUElzX0hOSEdwS2EyUVYyUk5CQw?oc=5", "source_name": "BioPharma Dive", "published_at": "2017-07-13T07:00:00+00:00", "published_display": "13 Jul 2017 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 60, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 71, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 20.4, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": -0.5, "twelve_week_move": -5.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.682028, "market_dynamics_buy_signal": false, "relative_strength": -10.978562, "fair_value_gap": -2.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.7872, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, -0.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 45, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "foreignpolicyjournal.com", "count": 1}, {"label": "GlobeNewswire", "count": 1}, {"label": "TradingView", "count": 1}, {"label": "BioPharma Dive", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "71/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, -0.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Vistin Pharma ASA (OB: VISTN) Stock Ex-Dividend Deadline Approaches as Income Investors Weigh Payout Sustainability"}], "updated_at": "2026-07-17T16:11:16.565519+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}